Novo's total revenue for the first nine months of 2026 was DKK 254 bn, up 11 percent from last year.
In a financial statement, Novo explained how the growth was partly built upon the release of the Wegovy pill, which had sold for DKK 5,4 bn during the third quarter.
“Growth was led by our obesity portfolio, with continued uptake of Wegovy® pill in the US and encouraging early launches internationally,” Novo CEO Mike Doustdar said in a comment.
BREAKING